Drugs / MRG-001
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05155839 | Jun 2019 → Oct 2022 | B-cell non-Hodgkin lymphoma | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06315608 | Jul 2025 → Jan 2026 overdue | amyotrophic lateral sclerosis | MedRegen LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06308926 | Dec 2024 → Feb 2026 overdue | acute respiratory distress syndrome, cytokine release syndrome | MedRegen LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06307522 | Sep 2024 → Sep 2026 overdue | alcoholic hepatitis | MedRegen LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05844527 | Nov 2023 → Sep 2024 | — | MedRegen LLC | Completed | No outcome recorded |
| Phase 2 | NCT04646603 | Dec 2021 → Mar 2022 | COVID-19, acute respiratory distress syndrome | MedRegen LLC | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRG-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05844527 ↗ |
| Route | Subcutaneous | “administered as a single subcutaneous (SC) injection” NCT04646603 ↗ |